B R I E F R E P O R T
In this study, we describe 13 patients with prosthetic infections due to Finegoldia magna (2% of our tested series).
Patients presented with either polymicrobial infection after an open fracture or nosocomial infection after recent prosthesis implantation. Molecular techniques are critical for diagnosis, and recommended antibiotic prophylaxis has poor activity against F. magna.
Formerly known as Peptococcus magnus or Peptostreptococcus magnus, Finegoldia magna was reclassified in 1999 with the use of 16S ribosomal RNA (rRNA) sequence into a new genus with a single species [1] . Phenotypic differentiation from Micromonas (Peptostreptococcus) micros is difficult. F. magna is a member of the normal human flora that colonizes skin and mucous membranes of the gastrointestinal tract. It has been isolated in pure culture from a range of serious infections [2] , mainly from soft tissue [3] . F. magna has been described in septic arthritis [4] , in prosthetic joint infection [5] [6] , and after rotator cuff repair [7] . In 1982, Fitzgerald et al [5] described 43 patients with anaerobic septic arthritis. Of these patients, 53% had prior joint surgery, and F. magna was the most common isolated pathogen [8] . In the French literature, 14 cases were reported in 1998 [9] , 5 of which occurred after anterior cruciate ligament (ACL) reconstruction (involving 4 artificial grafts) and 9 of which occurred with joint or wound infections after traumatic injuries or ruptured bone neoplasm treated with arthroplasty or osteosynthesis. Surprisingly, F. magna was frequently described as an agent of bone infection many years ago, but this etiology has been largely forgotten since 1982, when the most frequently referenced article was published, most likely because anaerobic culture is fastidious and costly [10] . We predict that molecular testing will increase the number of identified cases. Infected patients without prosthetic or osteosynthetic devices or ligamentoplasty were excluded from the study. Specimens were collected by needle aspiration or surgical biopsy only. Direct microscopic examination of the pus after Gram staining was performed to record the presence of polymorphonuclear leukocytes and bacteria. The sample was inoculated onto 5% sheep blood Columbia and chocolate agar (Bio-Mérieux), incubated at 37ЊC in a 5% CO 2 atmosphere and, in parallel, in an anaerobic atmosphere for 10 days. Pure bacterial cultures, obtained by picking isolated colonies, were identified with commercially available biochemical assays and, when needed, with previously described molecular identification methods [11, 12] . Samples were incubated overnight using proteinase K and lysis buffer at 55ЊC, and DNA was extracted with a MagNAPure LC instrument and the MagNAPure LC DNA isolation kit II (Roche Molecular Biochemicals), according to the manufacturer's instruction. Extracted DNA was PCR amplified with the 536F and rp2 (Eurogentec) primer pair targeting the 16S rRNA gene.
We searched the PubMed database with the following terms: joint infection, Finegoldia magna, Peptostreptococcus magnus, and anaerobes.
Results. We diagnosed 13 cases of F. magna, which caused 2% of osteoarthritis infections (Table 1) . In each case, microscopic examination of the aspirate was suggestive of infection, revealing at least 5 leukocytes per microscopic field. Susceptibility testing of major antibiotics was systematically included before treatment when the strains were available. In 7 cases, F. magna was the only identified agent; it was exclusively diagnosed by PCR in 4 cases and was diagnosed by PCR and culture in 3 cases. Six of these 7 patients were male; the mean age ‫ע(‬ standard deviation) was years. Four patients had hip pros-62.5 ‫ע‬ 9.4 thetic infection, 1 patient had undergone rotator cuff repair, and 2 patients had knee prosthetic infection. The symptomfree interval was !4 months after prosthetic device implantation, except for 1 woman (case 4) who had a knee injury 5 years after implantation and subsequently developed an infection. One patient (case 5) had human immunodeficiency virus infection (with a CD4 + lymphocyte count of 230 cells/mm 3 ), but no immunosuppressive conditions were found in the other cases. When a monomicrobial infection was diagnosed by means of PCR, empirical treatment with amoxicillin (100 mg/ kg per day, administered orally or intravenously) was initiated. One patient was treated with a medical regimen alone for 4 months. In the last 3 cases, the patients underwent surgical procedures: a 2-stage joint prosthesis exchange with a total duration of 6 months was performed in 2 cases, and a rotator cuff repair was performed immediately after the diagnosis in 1 case. One patient recently died from myocardial infarction. Evolution was favorable for the other patients. When diagnosis was made by means of culture (in 3 patients), the strains were susceptible to major antibiotics tested. In 1 case, the patient was lost to follow-up. For the 2 other patients, the medical regimens initiated by the surgeon were amoxicillin (100 mg/ kg/day, plus metronidazole at 30 mg/kg/day for 2 months and clindamycin at 2.4 g/day for 3 months).
In 6 cases, by means of needle aspiration, we diagnosed polymicrobial infections associated with gram-negative bacteria and staphylococci in open tibia fractures or eschars. In 7 cases, F. magna was the only agent identified in prosthetic joint infection or after rotator cuff repair.
Discussion. In each of the 13 cases described here, F. magna was regarded as a true pathogen and not as a contaminant, because only patients with a positive culture or positive PCR result from intraoperative samples recovered from different joint sites that exclusively isolated F. magna were considered. F. magna has been frequently described in bone and joint infections. In a series of 43 patients with anaerobic septic arthritis [5] , F. magna was recovered from 9 of 23 arthroplasties with postoperative arthritis and from 6 of 12 patients with posttraumatic septic arthritis. In a large French series of 14 cases [9] , it was mainly reported after ligament reconstruction or wound infection with underlying conditions (eg, prosthetic devices and immunosuppression). When combined with the published cases [6, 9] , the proportion of patients who received a diagnosis of F. magna as a sole agent (17 of 17 vs 4 of 10;
) was significantly higher for those with nosocomial P ! .001 infection than it was for those with posttraumatic infection. F. magna is one of the most common anaerobic pathogens and accounts for 5%-12% of all anaerobic isolates, but it has been largely forgotten as a cause of bone and joint infection [1, 3, 8] because of the costliness of anaerobic bacteria culture [10] . Microbiological tools are progressively evolving from culture to molecular biology; PCR amplification and 16S DNA sequencing have been used to diagnose bone and joint infections [12] . In our previous experience of 525 bone or joint samples, systematic PCR permitted 16 correct diagnoses in cases in which the samples yielded negative culture results [11] . Here, 4 patients received a diagnosis solely on the basis of PCR results, which illustrates the power of molecular testing in these circumstances.
We found that F. magna infection can be divided into 2 clinical entities. The first, characterized by posttraumatic infection, involves patients with open fractures. F. magna is generally a polymicrobial infection associated with gram-negative bacteria or staphylococci. In such cases, the pathogenic role of F. magna is questionable. In cases in which F. magna in the only pathogen recovered from culture, PCR analysis may detect up to 7 other (mainly anaerobic) species [11] . The second clinical entity is typically a nosocomial infection and involves patients who have received a hip or knee prosthesis followed promptly (within 4 months) by pain, mild fever, inflammation, and the eventual loosening of the prosthesis at the bone interface. In these cases, F. magna was the sole etiological agent. In some cases, the culture can remain sterile, and the diagnosis is made using PCR alone. In the literature [9, 13] , another clinical picture has been described that is characterized by an ACL reconstruction infection within 1 month after implantation.
F. magna is a member of the normal human flora that colonizes skin and is usually susceptible to b-lactam antibiotics and vancomycin. However, cefamandole, a commonly used antibiotic for orthopedic surgery prophylaxis, exhibited low activity against gram-positive anaerobic organisms, such as F. magna [14] , which may explain why F. magna infection occurs after orthopedic surgery.
In conclusion, physicians should suspect F. magna infection in cases of infection that occur !4 months after hip or knee prosthesis implantation, particularly if cultures appear to be sterile. The importance of molecular detection methods in identifying this microorganism in these circumstances cannot be overemphasized. Cefamandole is the major recommended antibiotic for prophylaxis, because it is active against the bacteria most often encountered, but physicians should keep in mind its poor activity against F. magna.
